4.8 Article

A mesoporous silica nanoparticle - PEI - Fusogenic peptide system for siRNA delivery in cancer therapy

期刊

BIOMATERIALS
卷 34, 期 4, 页码 1391-1401

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2012.10.072

关键词

siRNA; Delivery system; Magnetic mesoporous silica nanoparticles (M-MSNs) Polyethyleneimine (PEI); KALA peptide; VEGF

资金

  1. ERC from Science and Technology Commission of Shanghai [11DZ2211000]
  2. NNSF China [30900756, 81000656]
  3. SJTU [YG2009ZD203, YG2010ZD102, YG2011MS44, AE4160003, Z-416-001]

向作者/读者索取更多资源

RNA interference (RNAi) is widely regarded as a promising technology for disease treatment, yet one major obstacle for its clinical application is the lack of efficient siRNA delivery vehicles. In this study, we described a magnetic mesoporous silica nanoparticles (M-MSNs)-based, polyelectrolyte (polyethylenimine, PEI) and fusogenic peptide (KALA)-functionalized siRNA delivery system (denoted as M-MSN_siRNA@PEI-KALA), which was highly effective for initiating target gene silencing both in vitro and in vivo. The construction of this delivery system began with the encapsulation of siRNA within the mesopores of M-MSNs, followed by the coating of PEI on the external surface of siRNA-loaded M-MSNs and the chemical conjugation of KALA peptides. The as-prepared delivery vehicles, with notable siRNA protective effect and negligible cytotoxicity, could be easily internalized into cells, readily escape from the endolysosomes and release the loaded siRNA into the cytoplasm. As a result, the knockdown of enhanced green fluorescent protein (EGFP) and vascular endothelial growth factor (VEGF) in tumor cells were observed, both with excellent RNAi efficiencies. In the following in vivo experiments, the intratumoral injection of M-MSN_VEGF siRNA@PEI-KALA significantly inhibited the tumor growth, possibly by the suppression of neovascularization in tumors. To sum up, we have established a highly effective MSNs-based delivery system, which has great potential to serve as therapeutic siRNA formulation for cancer treatment. Crown Copyright (C) 2012 Published by Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据